Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00140660
Other study ID # LNH03-1B
Secondary ID
Status Terminated
Phase Phase 3
First received August 31, 2005
Last updated March 9, 2017
Start date December 2003
Est. completion date April 2012

Study information

Verified date March 2017
Source Lymphoma Study Association
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a multicentric randomized trial evaluating the efficacy of the combination R-ACVBP in patients 18 to 65 years with low risk localized diffuse large B-cell lymphoma.


Description:

Approximately 30 to 40% of diffuse large B cell lymphomas are localized at diagnosis (stage I-II). Until the seventies, radiotherapy was used as the single modality to treat these localized stages but no more than half of the patients were cured. From the eighties, anthracycline-based regimens combined or not with radiotherapy gave superior results in term of relapse free survival compared with radiotherapy alone. Later on Miller et al. published a randomized study showing that 3 cycles of CHOP combined with radiotherapy gave superior results in term of overall survival as compared with 8 cycles of CHOP. This study was recently updated with a follow up of more than 8 years and shows no more difference between the two arms, due to an excess of late mortality after the combined treatment.

Recently, two trials were conducted by the GELA to compare chemotherapy alone to a combined chemo-radiotherapy approach in patients with low risk localized diffuse large cell lymphoma (age-adjusted IPI = 0).

- The objective of the LNH 93-1 study was to compare, in patients aged from 18 to 60 years 3 cycles of CHOP followed by radiotherapy with chemotherapy alone consisting in 3 cycles of ACVBP. The ACVBP regimen includes a more intensive induction followed by a sequential consolidation. With a median follow up of 55 months, the results have shown a superiority of the ACVBP arm for both the 5 year event free (83% vs. 74%, p = 0.004) and overall survival (89% vs. 80%, p = 0.02).

- The LNH 93-4 study compared in patients >60 years the association of 4 cycles of CHOP + radiotherapy to the same regimen without irradiation. This study fails to demonstrate any benefit of the combined chemo-radiotherapy in term of survival, but indicates that chemotherapy alone is probably less toxic in patients older than 69 years.

Considering these two trials, we concluded that radiotherapy given after chemotherapy did not give any benefit to elderly patients treated for a low risk localized diffuse large cell lymphoma, and that ACVBP regimen was superior to 3 CHOP + radiotherapy in patients <60 years, and has to be considered as the treatment of reference in these patients.

Two other GELA trials contributed recently to improve the treatment of diffuse large B cell lymphoma and have to be considered for the elaboration of future studies:

- The objective of the LNH 98-5 study was to compare the association of CHOP + rituximab (R-CHOP) to the CHOP regimen alone in elderly patients with previously untreated large B-cell lymphoma. The analysis showed a significant superiority of the association CHOP + rituximab.

- The LNH 93-5 study compared the ACVBP regimen to the CHOP in patients aged from 61 to 69 years with aggressive lymphoma and at least one adverse prognostic factor according to the International Prognostic Index. Out of 703 patients included in this study, the results have shown the same complete response rate in the two arms, but a significantly better 3-year event free survival and overall survival in the ACVBP arm than in the CHOP arm. However, the benefit seems to be greater in patients <66 years, due to higher toxicity with the ACVBP regimen in elderly patients.

All the above-mentioned results led us to propose a randomized trial comparing ACVBP to ACVBP + rituximab (R-ACVBP) in previously untreated patients with low risk localized diffuse large B-cell lymphoma (age-adjusted IPI = 0), and to extend the upper age limit from 60 to 65 years.


Recruitment information / eligibility

Status Terminated
Enrollment 223
Est. completion date April 2012
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification).

- Age from 18 to 65 years.

- Patient not previously treated.

- Ann Arbor stage I or II.

- ECOG performance status < 2.

- Normal LDH.

- Negative HIV, HBV and HCV serologies 4 weeks (except after vaccination).

- Having previously signed a written informed consent.

Exclusion Criteria:

- Any other histological type of lymphoma. vAny history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in lymph node may be included.

- Central nervous system or meningeal involvement by lymphoma.

- Contra-indication to any drug contained in the chemotherapy regimens.

- Poor renal function (creatinin level >150 mmol/l), poor hepatic function (total bilirubin level >30 mmol/l, transaminases >2.5 maximum normal level).

- Poor bone marrow reserve as defined by neutrophils < 1.5 G/l or platelets < 100 G/l.

- Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.

- Any serious active disease (according to the investigator's decision).

- Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.

- Pregnant or lactating women

- Adult patient under tutelage.

Study Design


Intervention

Drug:
rituximab
375 mg/m2 on D1

Locations

Country Name City State
Belgium Groupe d'Etude des Lymphomes de l'adulte Mont-Godinne
France Hôpital Henri Mondor Créteil
France Hématologie CHU de Lille Lille
France Hématologie Adultes - Hôpital Necker Paris
France Hôpital Saint Louis Paris
France Service d'Hématologie - Centre Hospitalier Lyon-Sud Pierre-Bénite cedex
France Centre Hospitalier Robert Debré Reims
France Centre Henri Becquerel Rouen
France Hématologie CHU Purpan Toulouse
France Institut Gustave Roussy Villejuif
Switzerland Centre Pluridisciplinaire d'Oncologie, CHUV Lausanne

Sponsors (2)

Lead Sponsor Collaborator
Lymphoma Study Association Amgen

Countries where clinical trial is conducted

Belgium,  France,  Switzerland, 

References & Publications (4)

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. — View Citation

Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998 Jul 2;339(1):21-6. — View Citation

Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA).. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005 Mar 24;352(12):1197-205. — View Citation

Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte.. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003 Dec 15;102(13):4284-9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Event-free survival (EFS) events defined as death from any cause, relapse for complete responders (CR) and unconfirmed complete responders (CRu), progression during and after treatment and change of therapy. 4 years
Secondary Response rate at the end of the treatment 6 months
Secondary Disease-free survival for complete responders 4 years
Secondary Overall survival 4 years
Secondary additionnal toxicities with R-ACVBP number of SAE 4 years
See also
  Status Clinical Trial Phase
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Completed NCT01943682 - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Phase 1
Unknown status NCT00598624 - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Phase 2
Recruiting NCT02819583 - CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Phase 1/Phase 2
Completed NCT00275431 - Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies Phase 2
Completed NCT00225212 - Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma Phase 2
Completed NCT00591630 - Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation Phase 2
Completed NCT02374333 - Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy Phase 1
Terminated NCT01685606 - Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Phase 2
Recruiting NCT05389423 - Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas Phase 1
Terminated NCT00942409 - Study of Repeat Intranodal Injections of Ad-ISF35 Phase 2
Recruiting NCT02851589 - Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma Phase 1/Phase 2
Completed NCT00949741 - Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients N/A
Completed NCT01859819 - Treatment for Advanced B-Cell Lymphoma Phase 2
Completed NCT00791011 - Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat Phase 1
Completed NCT00144755 - R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma Phase 3
Completed NCT00144807 - ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma Phase 2
Completed NCT01300026 - AMG 319 Lymphoid Malignancy FIH Phase 1
Completed NCT00169195 - Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma Phase 2